Medulloblastoma Development: Tumor Biology Informs Treatment Decisions

CNS Oncol. 2015;4(2):79-89. doi: 10.2217/cns.14.58.

Abstract

Medulloblastoma is the most common malignant pediatric brain tumor. Current treatments including surgery, craniospinal radiation and high-dose chemotherapy have led to improvement in survival. However, the risk for recurrence as well as significant long-term neurocognitive and endocrine sequelae associated with current treatment modalities underscore the urgent need for novel tumor-specific, normal brain-sparing therapies. It has also provided the impetus for research focused on providing a better understanding of medulloblastoma biology. The expectation is that such studies will lead to the identification of new therapeutic targets and eventually to an increase in personalized treatment approaches.

Keywords: immunotherapy for pediatric brain tumors; medulloblastoma; molecular classification; mouse models and preclinical studies; targeted agents for clinical studies; tumor epigenomics; tumor genomics.

Publication types

  • Review

MeSH terms

  • Animals
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / genetics
  • Brain Neoplasms / metabolism
  • Brain Neoplasms / therapy*
  • Clinical Decision-Making
  • Clinical Trials as Topic
  • Humans
  • Medulloblastoma / diagnosis
  • Medulloblastoma / genetics
  • Medulloblastoma / metabolism
  • Medulloblastoma / therapy*